Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duration of oral anticoagulation for left ventricular thrombus after acute coronary syndrome
ISRCTN29145021Phase 2Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of apixaban, rivaroxaban and warfarin in Left ventricular thrombosis (LVT) and acute coronary syndrome (ACS) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Composite of systemic thromboembolism and all-cause mortality. Started Mar 2026; status: recruiting.
02
Drugs
apixabanrivaroxabanwarfarin
03
Conditions
Left ventricular thrombosis (LVT)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ISRCTN29145021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29145021.